Page last updated: 2024-10-26

etidronate and Myasthenia Gravis

etidronate has been researched along with Myasthenia Gravis in 1 studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sanchez-Ayaso, PA1
Garcia-Munozguren, S1
Salmeron, MP1

Other Studies

1 other study available for etidronate and Myasthenia Gravis

ArticleYear
[Ocular myasthenia revealed by risedronate].
    Revista de neurologia, 2012, Nov-16, Volume: 55, Issue:10

    Topics: Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Myasthenia Grav

2012